Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Lyell Immunopharma, Inc. (LYEL)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. They have assembled a world-class team, comprising some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT), including Drs. Rick Klausner, Nick Restifo, Stan Riddell and Crystal Mackall, who have each interrogated and elucidated the mechanisms of T cell biology and its interactions with cancer for decades. They believe the key to effective cell therapy is the mastery of the identity, fate and function of cells to create living medicines. They take a systematic, interrogative, cell biology-driven approach to overcome what they view as the two major barriers to successful ACT -- (1) T cell exhaustion and (2) lack of durable stemness -- through the application of their proprietary genetic and epigenetic reprogramming technologies, Gen-R and Epi-R. Their technologies are designed to be applied in a target and modality agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to fundamentally improve the properties of T cells needed to eradicate solid tumors. They believe their autologous T cell therapies will generate improved, durable clinical outcomes that are potentially curative for patients with solid tumors. They are building a multi-modality product pipeline across several solid tumor indications with high unmet needs and anticipate having four investigational new drug application (IND) submissions by the end of 2022.
Industry
Pharmaceutical Preparations
CEO CFO
Elizabeth Homans Charles Newton
Employees Founded
188 2018

Contacts

Address: 400 East Jamie Court, Suite 301 South San Francisco, California 94080

Telephone: (650) 695-0677

Web page: http://www.lyell.com

IPO information

First Trade Date 6/17/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 25
Shares Revised (MM) 25
Expected offer amount (MM) $425
Realized offer amount(MM) $425

Financial Data (last reporting year)

Market Cap (MM) $4128.11
Revenues (MM) $8.95
Net Income (Loss) (MM) $-230.28

Voting

What do you think will happen with the LYEL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Goldman Sachs/ BofA Securities/ JP Morgan/ Morgan Stanley
CO-Managers

Sector: Healthcare

Tweets about $LYEL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats